Akebia Therapeutics (AKBA) Reports Q4 Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
March 18, 2019 4:05 PM EDTSubstantial revenue growth opportunity for Auryxia following robust 2018 commercial performance
First regulatory submission for vadadustat expected in 2019 in Japan, following positive top-line results from pivotal phase 3 studies in Japanese subjects with anemia due to chronic kidney disease
Multiple vadadustat phase 3 readouts expected over next 18 months
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical... More
